SCHEMBL21158896

SCHEMBL21158896

COC(C(=O)N1C2CC1CN(C(C)(C)C)C2)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.42
RET P07949 1/20 0.41
ALDH1A1 P00352 2/20 0.36
GAA P10253 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
AGTR2 P50052 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CHRM1 P11229 1/20 0.35
CCNA2 P20248 2/20 0.35
CDK2 P24941 2/20 0.35
CCNA1 P78396 2/20 0.35
CYP2D6 P10635 2/20 0.35
HSD17B10 Q99714 2/20 0.35
CYP3A4 P08684 1/20 0.35
CYP1A2 P05177 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22030858 0.85 RET (0.45) RAB9ARETALDH1A1GAAL3MBTL1
SCHEMBL20148612 0.84 RET (0.42) RAB9ARETALDH1A1GAAL3MBTL1
SCHEMBL22811848 0.82 RET (0.45) RAB9ARETALDH1A1GAACHRM1
SCHEMBL22030861 0.82 RET (0.41) RAB9ARETALDH1A1GAAL3MBTL1
SCHEMBL14211221 0.80 RAB9A (0.41) RAB9ARETALDH1A1GAAL3MBTL1
SCHEMBL18713065 0.76 CHRM1 (0.53) RAB9AALDH1A1GAAKMT2AMEN1
SCHEMBL20152353 0.73 GAA (0.44) RAB9ARETALDH1A1GAAL3MBTL1
SCHEMBL14211302 0.70 CHRNB2 (0.49) RAB9AALDH1A1GAAL3MBTL1KMT2A
SCHEMBL21158897 0.70 RET (0.40) RETALDH1A1CYP3A4CYP1A2
SCHEMBL21158898 0.69 RET (0.42) RETALDH1A1CYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10953005-B1 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2021-03-23 US disclosed
US-10555944-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ELI LILLY AND COMPANY (US) 2020-02-11 US disclosed
US-20190183886-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2019-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10555944-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF RAB9A 766/4885RET 1/4885ALDH1A1 2868/4885
US-10953005-B1 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF RAB9A 766/4885RET 1/4885ALDH1A1 2868/4885
US-20190183886-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF RAB9A 766/4885RET 1/4885ALDH1A1 2868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.